Market capitalization | $447.82m |
Enterprise Value | $453.71m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.30 |
P/S ratio (TTM) P/S ratio | 18.06 |
P/B ratio (TTM) P/B ratio | 6.40 |
Revenue growth (TTM) Revenue growth | 49.65% |
Revenue (TTM) Revenue | $24.79m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a KemPharm, Inc. forecast:
8 Analysts have issued a KemPharm, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 25 25 |
50%
50%
|
|
Gross Profit | 6.59 6.59 |
56%
56%
|
|
EBITDA | -81 -81 |
85%
85%
|
EBIT (Operating Income) EBIT | -86 -86 |
95%
95%
|
Net Profit | -85 -85 |
113%
113%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
Head office | United States |
CEO | Neil McFarlane |
Employees | 69 |
Founded | 2006 |
Website | zevra.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.